Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(165 produtos)
- Bcr-Abl(117 produtos)
- EGFR(562 produtos)
- FAK(72 produtos)
- FLT(89 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(177 produtos)
- JAK(245 produtos)
- PDGFR(127 produtos)
- RAAS(86 produtos)
- Src(82 produtos)
- Syk(37 produtos)
- Trombina(52 produtos)
- VDA(2 produtos)
- VEGFR(239 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2242 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DB1113
CAS:DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.Fórmula:C59H68F3N13O6SCor e Forma:SolidPeso molecular:1144.31PROTAC BTK Degrader-6
CAS:PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expressionFórmula:C45H47N11O6Pureza:98%Cor e Forma:SolidPeso molecular:837.92MRG003
MRG003 is an antibody-drug conjugate (ADC) composed of the humanized anti-EGFR IgG1 monoclonal antibody, Becotatug, coupled with MMAE. These components are linked through a valine-citrulline (valine-citrulline) connector, forming the Drug-Linker conjugate VcMMAE within the ADC.Cor e Forma:Odour LiquidBefotertinib
CAS:Befotertinib (D-0316) is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.Fórmula:C29H32F3N7O2Pureza:99.83%Cor e Forma:SolidPeso molecular:567.61Ref: TM-T39275
1mg84,00€5mg177,00€10mg281,00€25mg497,00€50mg708,00€100mg973,00€1mL*10mM (DMSO)222,00€EGFR-IN-116
EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.Fórmula:C26H22N6O2SPeso molecular:482.1525VnP-16
VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activatesFórmula:C82H112N20O17Pureza:98%Cor e Forma:SolidPeso molecular:1649.89PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Fórmula:C47H54F2N8O13Cor e Forma:SolidPeso molecular:976.97Syk Inhibitor II hydrochloride
CAS:Syk signaling is key in lupus. Syk inhibitors reduce inflammation and sepsis severity in FcgRIIb-/- mice, lowering cytokines and organ damage.Fórmula:C14H16ClF3N6OPureza:99.05%Cor e Forma:SolidPeso molecular:376.77ALK-IN-9
CAS:ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.Fórmula:C20H21FN6O3Cor e Forma:SolidPeso molecular:412.425FLT3-IN-22
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.Fórmula:C24H22N6O2Cor e Forma:SolidPeso molecular:426.47MS9427 TFA
MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.Fórmula:C50H59ClF4N8O14Cor e Forma:SolidPeso molecular:1107.5PF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Fórmula:C46H50F3N13O8Pureza:98%Cor e Forma:SolidPeso molecular:969.97FLT3-IN-21
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase.Fórmula:C20H22FN5O2Cor e Forma:SolidPeso molecular:383.42PROTAC FAK degrader 1
CAS:PROTAC FAK degrader 1 is a selective and potent degrader of focal adhesion kinase (Fak) (IC50 of 6.5 nM).
Fórmula:C47H56F3N9O8S2Pureza:98%Cor e Forma:SolidPeso molecular:996.13K882
K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.Fórmula:C18H16N2O2Cor e Forma:SolidPeso molecular:292.33BTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Fórmula:C23H32N4O5Cor e Forma:SolidPeso molecular:444.532VEGFR-2-IN-64
VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.Fórmula:C72H123N9O6Cor e Forma:SolidPeso molecular:1210.8EGFR/DHFR-IN-1
EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR, with IC50 values of 0.151 µM and 0.541 µM, respectively. It induces cell cycle arrest in the G0-G1 and S phases.Fórmula:C24H26N4O5S2Peso molecular:514.13446FGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].
Fórmula:C26H27N4O6PPureza:98%Cor e Forma:SolidPeso molecular:522.49EGFR-PK/JNK-2-IN-1
EGFR-PK/JNK-2-IN-1 (Compound 6c) is a dual inhibitor of EGFR-PK and JNK-2, with IC50 values of 2.7 and 3.0 μM, respectively. It can induce apoptosis and cause cell cycle arrest at various stages. This compound is applicable in cancer research.Fórmula:C22H17ClN4O3SPeso molecular:452.07099
